Alex Fotopoulos
Director Técnico/Científico/I+D en PASSAGE BIO, INC. .
Fortuna: 96 005 $ al 30/04/2024
Cargos activos de Alex Fotopoulos
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| PASSAGE BIO, INC. | Director Técnico/Científico/I+D | 01/07/2019 | - |
Historial de carrera de Alex Fotopoulos
Antiguos cargos conocidos de Alex Fotopoulos.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Director Técnico/Científico/I+D | 01/11/2017 | 01/07/2019 |
| DIMENSION THERAPEUTICS INC | Director Técnico/Científico/I+D | 01/05/2016 | 01/11/2017 |
| MOMENTA PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/08/2011 | 01/05/2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01/08/1994 | 01/01/2011 |
Formación de Alex Fotopoulos.
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Chief Tech/Sci/R&D Officer | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorial
| Health Technology | 6 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Alex Fotopoulos
- Experiencia
